VEGF-Targeted Therapy in Metastatic Renal Cell Carcinoma
Open Access
- 1 March 2005
- journal article
- retracted article
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 10 (3) , 191-197
- https://doi.org/10.1634/theoncologist.10-3-191
Abstract
Purpose. To review the biology of renal cell carcinoma (RCC) and the clinical results of vascular endothelial growth factor (VEGF) blockade in metastatic RCC. Methods. A review of relevant published literature regarding VEGF, von Hippel-Lindau (VHL) gene inactivation, and VEGF overexpression in RCC was performed. Further, a review of the mechanism, toxicity, and clinical development of VEGF-targeted therapy in metastatic RCC was undertaken. Results. VHL tumor suppressor gene inactivation is observed in the majority of clear cell RCC cases, leading to VEGF overexpression. Therapy with agents directed against the VEGF protein or the VEGF receptor have demonstrated initial clinical activity in metastatic RCC. Conclusions. Therapeutic targeting of VEGF in RCC has strong biologic rationale. Substantial clinical activity has been reported in initial clinical trials with VEGF-targeting agents. Further investigation is needed to optimally use these agents for maximal clinical benefit.Keywords
This publication has 35 references indexed in Scilit:
- Cancer and Leukemia Group B 90206Clinical Cancer Research, 2004
- Hypoxia Inducible Factor Activates the Transforming Growth Factor-α/Epidermal Growth Factor Receptor Growth Stimulatory Pathway in VHL-/- Renal Cell Carcinoma CellsJournal of Biological Chemistry, 2003
- Overproduction of Vascular Endothelial Growth Factor Related to von Hippel-Lindau Tumor Suppressor Gene Mutations and Hypoxia-Inducible Factor-1α Expression in Renal Cell Carcinomas.Journal of Urology, 2003
- Vascular endothelial growth factor overexpression is correlated with von Hippel‐Lindau tumor suppressor gene inactivation in patients with sporadic renal cell carcinomaCancer, 2002
- VHL mutations and their correlation with tumour cell proliferation, microvessel density, and patient prognosis in clear cell renal cell carcinomaThe Journal of Pathology, 2001
- Hypoxia Inducible Factor-α Binding and Ubiquitylation by the von Hippel-Lindau Tumor Suppressor ProteinJournal of Biological Chemistry, 2000
- Vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) delays and induces escape from senescence in human dermal microvascular endothelial cellsOncogene, 1997
- Vascular Endothelial Growth Factor Expression is Increased in Renal Cell CarcinomaJournal of Urology, 1997
- Mutations of the VHL tumour suppressor gene in renal carcinomaNature Genetics, 1994
- Identification of the von Hippel-Lindau Disease Tumor Suppressor GeneScience, 1993